A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice.

Guo, Hanfei; Qian, Lei; Chen, Xiao; Zhao, Yuguang; Song, Wei; Guan, Yanjie; Cui, Jiuwei

Guo, Hanfei; Qian, Lei; Chen, Xiao; Zhao, Yuguang; Song, Wei; Guan, Yanjie; Cui, Jiuwei.

Afiliação

Guo H; Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Qian L; Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Chen X; Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Zhao Y; Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Song W; Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Guan Y; Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.
Cui J; Cancer Center, The First Hospital of Jilin University, Changchun 130021, China.

Open Med (Wars) ; 17(1): 53-60, 2022.

Article em En | MEDLINE | ID: mdl-34993345

Palavras-chave

hyperprogressive disease; immune checkpoint inhibitors; prognostic marker

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Open Med (Wars) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Polônia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google